Pivotal year as Syntopix shakes up board

ACNE specialist Syntopix Group has announced a boardroom reshuffle that will see the appointment of a new chairman in a bid to charm City investors.
By The Newsroom
Published 4th Feb 2010, 10:10 BST
Updated 4th Feb 2010, 10:11 BST

The company, which was spun out of the University of Leeds and is based in Bradford, said current non-executive chairman Dr Rod Adams will stand down to be replaced by Tom Bannatyne.

Mr Bannatyne has more than 20 years' experience in the investment industry, and formerly managed hedge fund Tudor Group's European equities business.

Hide Ad
Hide Ad

The company also said Dr Anne Eady and Dr Helen Shaw will step down as non-executive directors.

However, Dr Eady, one of the company's founders, will remain scientific director.

Chief executive Stephen Jones said: "2010 will be a pivotal year for Syntopix, building on the encouraging progress in 2009 and I am delighted that Tom will be joining the board of Syntopix at this important time.

"His impressive investment experience will be extremely valuable, providing Syntopix with a stronger City presence and strategic guidance as it enters a new phase of heightened commercial development, targeting a multi-billion global consumer healthcare market.

"The Syntopix team looks forward to working with him."

Related topics:BradfordUniversity of Leeds